Oruka Shares Rise More Than 13% After Positive Psoriasis Trial Results
Guggenheim reaffirmed its bullish outlook on Oruka Therapeutics, saying its experimental psoriasis treatment could generate $7 billion in peak sales. Shares were up more than 13% at the time of writing.
Oruka Therapeutics (ORKA) was on investors’ radar on Monday after positive trial results for its experimental psoriasis treatment prompted Guggenheim to reaffirm its bullish outlook on the company.ORKA shares were up over 13% at the time of writing, having breached their 50-day moving average (50-D…